In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline
In its third quarter report, Oncorus highlighted that it would report updated Phase I data on its lead candidate, an oncolytic virus therapy for solid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
